title: [Evolution of monoclonal antibodies in cancer treatment].
abstract: Since late 90s of last century the new age of directed therapy began using mainly biological constructs produced in rodents called monoclonal antibodies. The side effects of monoclonal antibodies were a challenge for pharmaceutical companies to improve the biological properties of these biological drugs. The humanization of monoclonal constructs was an idea to improve monoclonal antibodies next generation activity cancer cell reduction in humans. Moreover for some other patients sensitive for monoclonal antibodies therapy could also potentially induce immunological differences that might imply on human health. The new idea related to monoclonal antibodies was to design a small molecule constructs of nanoantibodies with ability to enter into cells. Such small molecules could find their targets inside human cells, even in nuclei leading to differences in cancer cells expression. The existing knowledge on monoclonal antibodies as well as directed activity of nanoantibodies could improve anticancer treatment efficancy of diseases.
authors.affiliation: Department of Cytobiochemistry, Lodz University, 141/143 Pomorska St., 90-236 Łódź, Poland.
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Kubczak
authors.affiliation: Department of Cytobiochemistry, Lodz University, 141/143 Pomorska St., 90-236 Łódź, Poland.
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Rogalińska
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D000074322:Antineoplastic Agents, Immunological
keywords: CD20 antigen; anticancer therapy; monoclonal antibodies; nanoantibodies